AmyGottliebMD

PubMed

• 2 citations
  Moving the Needle on Gender Equity: a Call for Personal and Organizational Action.
  Carol K. Bates, Amy S. Gottlieb> ;Journal of General Internal Medicine. 2019 Jan 2
• 8 citations
  Job Negotiations in Academic Medicine: Building a Competency-Based Roadmap for Residents and Fellows
  Rebecca A. Berman, Amy S. Gottlieb> ;Journal of General Internal Medicine. 2019 Jan 1
• 50 citations
  Rationale and Models for Career Advancement Sponsorship in Academic Medicine: The Time Is Here; the Time Is Now.
  Amy S. Gottlieb, Elizabeth L. Travis> ;Academic Medicine. 2018 Jan 1
• A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
  Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kri...> ;Br. J. Dermatol.. 2016-08-01
• Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized c...
  Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB> ;Br. J. Dermatol.. 2015-12-01
• Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
  Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R> ;Br. J. Dermatol.. 2015-10-01
• Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.
  Punwani N, Burn T, Scherle P, Flores R, Shi J, Collier P, Hertel D, Haley P, Lo Y, Waeltz P, Rodgers J, Shepard S, Vaddi K, Yeleswaram S, Levy R, Williams W, Gottlieb AB> ;Br. J. Dermatol.. 2015-10-01
• Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
  Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R> ;Br. J. Dermatol.. 2015-10-01
• Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.
  Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC> ;Br. J. Dermatol.. 2015-09-01
• Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
  Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S> ;Br. J. Dermatol.. 2015-02-01
• Diagnosing and treating psoriatic arthritis: an update.
  Boehncke WH, Qureshi A, Merola JF, Thaçi D, Krueger GG, Walsh J, Kim N, Gottlieb AB> ;Br. J. Dermatol.. 2014-04-01
• A teachable moment for providers and patients alike: contraceptive counseling when prescribing medications with teratogenic potential.
  Amy S. Gottlieb> ;Journal of Women's Health. 2013 Sep 30
• A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
  Gottlieb, A. B.,Langley, R. G.,Strober, B. E.,Papp, K. A.,Klekotka, P.,Creamer, K.,Thompson, E. H.,Hooper, M.,Kricorian, G.> ;Br. J. Dermatol.. 2012 Sep
• Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with...
  Reich K, Ortonne J, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P> ;Br. J. Dermatol.. 2012-07-01
• Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
  Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA> ;Br. J. Dermatol.. 2011-09-01
• 2 citations
  Interpersonal violence screening for ambulatory gynecology patients.
  Jennifer A. Kang, Amy S. Gottlieb, Christina Raker, Sonia S. Aneja, Lori A. Boardman> ;Obstetrics and Gynecology. 2010 Jun 1
• Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
  Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A> ;Br. J. Dermatol.. 2008-09-01
• 16 citations
  Intimate partner violence: a clinical review of screening and intervention
  Amy S. Gottlieb> ;Women's Health. 2008 Aug 18
• 37 citations
  Uterine necrosis: a complication of uterine compression sutures.
  Amy G. Gottlieb, Santosh Pandipati, Karlotta M. Davis, Ronald S. Gibbs> ;Obstetrics and Gynecology. 2008 Aug 1
• 13 citations
  Nontraditional Sonographic Pearls in Estimating Gestational Age
  Amy G. Gottlieb, Henry L. Galan> ;Seminars in Perinatology. 2008 Jun 1
• Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
  Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB> ;Br. J. Dermatol.. 2008-05-01
• Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.
  Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M, Chiou CF, Patel V, Jahreis A> ;Br. J. Dermatol.. 2007-12-01
• 35 citations
  Shoulder dystocia: an update.
  Amy G. Gottlieb, Henry L. Galan> ;Obstetrics and Gynecology Clinics of North America. 2007 Sep 1
• Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
  Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A> ;Br. J. Dermatol.. 2007-01-01
• Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
  Gottlieb AB, Griffiths CEM, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne J, Todd G, Cherill R, Marks I, Emady-Azar S, Paul CF> ;Br. J. Dermatol.. 2005-06-01
• Join now to see all